Hinge Health Inc. (NYSE:HNGE) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Hinge Health Inc. (NYSE:HNGE) have been given an average recommendation of “Moderate Buy” by the twenty ratings firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, sixteen have given a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $67.40.

Several equities research analysts have recently issued reports on HNGE shares. Wall Street Zen raised Hinge Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 23rd. KeyCorp set a $55.00 price objective on Hinge Health in a research note on Wednesday, February 11th. Evercore reaffirmed an “outperform” rating and issued a $45.00 price objective on shares of Hinge Health in a research note on Wednesday, April 8th. Zacks Research raised Hinge Health from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Finally, Raymond James Financial reaffirmed an “outperform” rating and issued a $70.00 price objective on shares of Hinge Health in a research note on Wednesday, May 6th.

Hinge Health Price Performance

NYSE HNGE opened at $56.13 on Monday. The stock has a market capitalization of $4.34 billion and a PE ratio of -4.55. The business has a 50 day simple moving average of $46.06 and a two-hundred day simple moving average of $44.68. Hinge Health has a 1-year low of $30.08 and a 1-year high of $62.18.

Hinge Health (NYSE:HNGE) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.33. The business had revenue of $182.31 million during the quarter. Hinge Health had a negative return on equity of 310.62% and a negative net margin of 78.95%.The business’s quarterly revenue was up 47.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.30 EPS. On average, analysts anticipate that Hinge Health will post 1.21 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Daniel Antonio Perez sold 45,456 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $55.05, for a total value of $2,502,352.80. Following the completion of the sale, the chief executive officer directly owned 35,470 shares of the company’s stock, valued at $1,952,623.50. This trade represents a 56.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James Budge sold 5,907 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $53.79, for a total value of $317,737.53. Following the completion of the sale, the chief financial officer directly owned 445,386 shares of the company’s stock, valued at $23,957,312.94. The trade was a 1.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 587,932 shares of company stock valued at $29,116,997 over the last quarter. Company insiders own 18.92% of the company’s stock.

Institutional Investors Weigh In On Hinge Health

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its position in Hinge Health by 22.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,237,839 shares of the company’s stock valued at $60,753,000 after purchasing an additional 228,234 shares in the last quarter. UBS Group AG raised its position in Hinge Health by 168.8% during the 4th quarter. UBS Group AG now owns 356,701 shares of the company’s stock valued at $16,569,000 after purchasing an additional 223,980 shares in the last quarter. Tudor Investment Corp ET AL raised its position in Hinge Health by 25.9% during the 3rd quarter. Tudor Investment Corp ET AL now owns 376,266 shares of the company’s stock valued at $18,467,000 after purchasing an additional 77,464 shares in the last quarter. First Eagle Investment Management LLC bought a new stake in Hinge Health during the 3rd quarter valued at $4,074,000. Finally, Braidwell LP bought a new stake in Hinge Health during the 3rd quarter valued at $44,686,000.

About Hinge Health

Hinge Health (NYSE: HNGE) is a digital musculoskeletal (MSK) clinic that provides end-to-end solutions for the prevention and management of musculoskeletal conditions. The company’s platform combines wearable motion sensors, personalized exercise therapy guided by licensed physical therapists, and behavioral health coaching to deliver tailored treatment plans. By integrating technology with evidence-based clinical protocols, Hinge Health aims to reduce pain, improve mobility and decrease reliance on more invasive interventions such as surgery or opioid prescriptions.

Founded in 2015 and headquartered in San Francisco, Hinge Health partners with employers, health plans and other payers to offer its self-directed, app-based programs.